Preview Mode Links will not work in preview mode

Eye Care Insider

Jul 14, 2021

In this second episode of a three-part series, John B. Pinto discusses the job market for early-career professionals and new graduates, his perspective on what ophthalmologists have learned from the pandemic and the role telemedicine will play in the future of ophthalmology.

  • Intro :14
  • What is the current negotiation position in the market for early-career and new graduate ophthalmic practice physicians? :41
  • I’d love to hear your perspective on what we have learned about our practices after a year of this pandemic 3:35
  • How is the telemedicine trend going now? Is telemedicine here to stay? 11:09
  • Tell us about your upcoming book and your insight into it? 12:59
  • Stay tuned for the next episode of this special three-part miniseries 17:38

John B. Pinto is president of J. Pinto & Associates, Inc. He is also a practice consultant and the author of several books on ophthalmic practice management, including John Pinto’s Little Green Book of Ophthalmology, UP (with Corinne Wohl), Simple, and Ophthalmic Leadership.

UP: Taking Ophthalmic Administrators and Their Management Teams to the Next Level of Skill, Performance and Career Satisfaction, Second Edition is a powerful, practical workbook by Corinne Wohl, MHSA, COE and John B. Pinto designed to take ophthalmic administrators and practice managers to the next level of their careers, offering practical tips, concrete advice, and a step-by-step guide for any hurdle they face. Available now for purchase at Receive 20% off with promo code PINTO20.

We’d love to hear from you! Send your comments/questions to Dr. Mali at Follow us on Twitter @Healio_OSN.

Disclosures: The Wyanoke Group is the parent company of Healio and SLACK Books. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron.